Delivery of multifactorial interventions by nurse and dietitian teams in a community setting to prevent diabetic complications: a quality-improvement report.

BACKGROUND Clinical trials showed that multifactorial interventions can prevent microvascular and macrovascular complications of diabetes, but delivery of proven therapies in clinical practice is often suboptimal. STUDY DESIGN Quality-improvement report. SETTING & PARTICIPANTS Teams composed of a nurse and a dietitian were established in 5 communities, 2 urban and 3 rural, in Northern Alberta, Canada, and provided care for 424 individuals with diabetes plus hypertension or albuminuria. QUALITY-IMPROVEMENT PLAN: To promote the use of proven therapies and achieve tight control of risk factors through community teams providing lifestyle advice, adjusting therapy using algorithms and regular follow-up. OUTCOMES The proportion of subjects prescribed angiotensin-converting enzyme-inhibitor, statin, and antiplatelet therapy and the proportion of subjects reaching targets for blood pressure (<130/80 mm Hg), blood glucose (hemoglobin A(1c) [HbA(1c)] < 7%), and low-density lipoprotein cholesterol (<96 mg/dL). MEASUREMENTS Blood pressure, HbA(1c), low-density lipoprotein cholesterol, albumin-creatinine ratio, weight, and estimated glomerular filtration rate from serum creatinine. RESULTS Blood pressure, HbA(1c), and low-density lipoprotein cholesterol levels improved during follow-up (133 +/- 19/74 +/- 11 versus 129 +/- 17/71 +/- 10 mm Hg, 8.1% +/- 1.9% versus 7.5% +/- 1.3%, and 104 +/- 35 versus 93 +/- 31 mg/dL, respectively; P < 0.001 for all), whereas there was no increase in weight (95 +/- 22 versus 95 +/- 23 kg; P = 0.3). The proportion of patients prescribed angiotensin-converting enzyme-inhibitor, lipid-lowering, and antiplatelet therapy increased (37% versus 60.1%; P < 0.001), as did the proportion of patients reaching targets for blood pressure, low-density lipoprotein cholesterol (43.5% versus 55% and 43.4% versus 61.6%, respectively; P < 0.001), and HbA(1c) levels (32.1% versus 38.8%; P < 0.05). LIMITATIONS Short duration of follow-up and absence of economic evaluation, validity, and generalizability require confirmation in clinical trials and other settings. CONCLUSIONS Delivery of multifactorial interventions by nurse/dietitian teams in a community setting appears feasible and may achieve clinically significant improvements in blood pressure, lipids, and glycemic control, which would be expected to decrease cardiovascular morbidity and mortality.

[1]  M. Nahas The global challenge of chronic kidney disease. , 2005 .

[2]  K. Basu,et al.  Drug coverage in Canada: who is at risk? , 2005, Health policy.

[3]  F. McAlister,et al.  Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis , 2004, Canadian Medical Association Journal.

[4]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[5]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[6]  F. Hutchison,et al.  Prospective analysis of global costs for maintenance of patients with ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[8]  N. Freemantle,et al.  Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. , 2003, Diabetes care.

[9]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[10]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[11]  M. Massi-Benedetti The Cost of Diabetes Type II in Europe The CODE-2 Study , 2002, Diabetologia.

[12]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Paul Fenn,et al.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) , 2000, BMJ : British Medical Journal.

[14]  H. Morrison,et al.  End-stage renal disease in Canada: prevalence projections to 2005. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[16]  B. Peterson,et al.  Nurse Case Management To Improve Glycemic Control in Diabetic Patients in a Health Maintenance Organization , 1998, Annals of Internal Medicine.

[17]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[18]  Philip D. Harvey,et al.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.

[19]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[20]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[21]  J. Piercy,et al.  Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. , 1997, QJM : monthly journal of the Association of Physicians.

[22]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[23]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[24]  C. Mogensen Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy , 1982, British medical journal.

[25]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[26]  Clare Bradley,et al.  Handbook of Psychology and Diabetes : A Guide to Psychological Measurement in Diabetes Research and Practice , 1994 .